Venatorx Pharmaceuticals has been awarded an NIH R01 biodefense grant for novel approaches to address resistant category B food and water-borne pathogens. The company may receive up to $4.3M in funding under the grant.
Venatorx Pharmaceuticals has been awarded an NIH R01 biodefense grant for novel approaches to address resistant category B food and water-borne pathogens. The company may receive up to $4.3M in funding under the grant.
| You are using a browser that is not supported. Please consider changing your browser |